A randomized controlled trial of vitamin D3 supplementation in African American women
A randomized controlled trial of vitamin D3 supplementation in African American women
复制标题
DOI：
10.1001/archinte.165.14.1618
复制
发表时间：
2005-07-25
影响因子：
--
通讯作者：
Yeh, J
中科院分区：
文献类型：
--
作者：
Aloia, JF;Talwar, SA;Yeh, J
背景资料：我们进行了一项随机，安慰剂对照，双盲试验，以测试的假设，即维生素D-3补充剂将防止骨质流失的钙充满，非洲裔美国人绝经后women.Methods：二百零八健康的黑人绝经后妇女，50至75岁，被分配到接受安慰剂或20微克/天（800国际单位）的维生素D-3。提供钙补充剂，以确保钙的总摄入量为1200至1500 mg/d。2年后，活性组的维生素D-3剂量增加到50 μ g/d（2000 IU），研究再持续一年。每6个月测量一次骨密度（BMD）。骨转换，维生素D代谢产物，和甲状旁腺激素（PTH）水平的标志物进行了测量serum.Results：有没有在整个研究中的活性和对照组之间的BMD显着差异。血清25-羟维生素D水平与骨丢失率之间也没有关系。两组患者术后1年时全身、髋关节和桡骨的BMD均增加。在3年内，这些部位的BMD每年下降0.26%至0.55%。安慰剂组和活性药物组的腰椎BMD略有增加。血清PTH水平或骨转换标志物没有持续变化，尽管两组在3个月时PTH均短暂下降。没有显着的不良事件归因于维生素D supplement.Conclusions：有没有观察到的影响，维生素D-3补充剂对骨质流失或骨转换标志物的钙，绝经后非洲裔美国妇女。需要进一步研究，以确定这些发现是否适用于其他族裔群体的妇女。
Background: We conducted a randomized, placebo-controlled, double-blind trial to test the hypothesis that vitamin D-3 supplementation would prevent bone loss in calcium-replete, African American postmenopausal women.Methods: Two hundred eight healthy black postmenopausal women, 50 to 75 years of age, were assigned to receive either placebo or 20 mu g/d (800 IU) of vitamin D-3. Calcium supplements were provided to ensure a total calcium intake of 1200 to 1500 mg/d. After 2 years, the vitamin D-3 dose was increased to 50 mu g/d (2000 IU) in the active group, and the study continued for an additional year. Bone mineral density (BMD) was measured every 6 months. Markers of bone turnover, vitamin D metabolites, and parathyroid hormone (PTH) levels were measured in serum.Results: There were no significant differences in BMD between the active and control groups throughout the study. There was also no relationship between serum 25-hydroxyvitamin D levels attained and rates of bone loss. There was an increase in BMD of the total body, hip, and radius at 1 year in both groups. Over the 3 years, BMD declined at these sites by 0.26% to 0.55% per year. The BMD of the lumbar spine increased slightly in the placebo and active groups. There were no persistent changes in serum PTH levels or the markers of bone turnover, although there was a transient decline in PTH in both groups at 3 months. No significant adverse events were attributed to vitamin D supplementation.Conclusions: There was no observed effect of vitamin D-3 supplementation on bone loss or bone turnover markers in calcium-replete, postmenopausal African American women. Further studies are needed to determine if these findings are applicable to women of other ethnic groups.